These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30860040)

  • 21. CMS retreats on Part D rule intended to reduce drug costs and improve access.
    Dickson V
    Mod Healthc; 2014 Mar; 44(11):10. PubMed ID: 24830094
    [No Abstract]   [Full Text] [Related]  

  • 22. The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2004 Feb; 350(6):608-13. PubMed ID: 14762190
    [No Abstract]   [Full Text] [Related]  

  • 23. Exploring the rise in American pharmaceutical prices.
    Marwaha A
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(2):11-5. PubMed ID: 12099112
    [No Abstract]   [Full Text] [Related]  

  • 24. The Canadians are killing us.
    Struble RA
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58-9. PubMed ID: 12592981
    [No Abstract]   [Full Text] [Related]  

  • 25. The Reach of the 340B Drug Pricing Program.
    Albrecht J; Mudahar S
    JAMA Dermatol; 2015 Sep; 151(9):923-4. PubMed ID: 25993384
    [No Abstract]   [Full Text] [Related]  

  • 26. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
    Dusetzina SB; Bach PB
    JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
    Greene JA; Padula WV
    N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
    [No Abstract]   [Full Text] [Related]  

  • 28. Rebates-The Little-Known Factor Behind Increasing Drug List Prices.
    Rubin R
    JAMA; 2020 Mar; 323(9):812-813. PubMed ID: 32125400
    [No Abstract]   [Full Text] [Related]  

  • 29. Expensive Medicine: Drug prices are increasingly hard to swallow. Effective remedies prove elusive.
    Bell H
    Minn Med; 2017 May; 100(3):10-17. PubMed ID: 30452131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disclosing Prescription-Drug Prices in Advertisements - Legal and Public Health Issues.
    Dusetzina SB; Mello MM
    N Engl J Med; 2018 Dec; 379(24):2290-2293. PubMed ID: 30428275
    [No Abstract]   [Full Text] [Related]  

  • 31. Copayment coupons undermine formularies.
    Manag Care; 2011 Dec; 20(12):63. PubMed ID: 22259878
    [No Abstract]   [Full Text] [Related]  

  • 32. Gift giving.
    Raszkowski RR
    S D J Med; 2002 Dec; 55(12):513-4. PubMed ID: 12516357
    [No Abstract]   [Full Text] [Related]  

  • 33. Rx: Canadian drugs.
    Bugden S
    N Engl J Med; 2004 Mar; 350(11):1155. PubMed ID: 15014193
    [No Abstract]   [Full Text] [Related]  

  • 34. New rules for US drug reimbursement.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
    [No Abstract]   [Full Text] [Related]  

  • 35. US drug industry group launches campaign to defend pricing.
    McCarthy M
    BMJ; 2016 Sep; 354():i4902. PubMed ID: 27612867
    [No Abstract]   [Full Text] [Related]  

  • 36. Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals.
    Feldman WB; Rome BN; Brown BL; Kesselheim AS
    JAMA Intern Med; 2022 Jan; 182(1):83-86. PubMed ID: 34747978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription-drug coupons--no such thing as a free lunch.
    Ross JS; Kesselheim AS
    N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672
    [No Abstract]   [Full Text] [Related]  

  • 38. State Initiatives to Control Medication Costs--Can Transparency Legislation Help?
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2016 Jun; 374(24):2301-4. PubMed ID: 27305189
    [No Abstract]   [Full Text] [Related]  

  • 39. Shades of gray. Secondary drug distributors raise questions.
    Lee J
    Mod Healthc; 2011 Oct; 41(41):10, 12. PubMed ID: 22111494
    [No Abstract]   [Full Text] [Related]  

  • 40. Plenty of green in gray market. There's more at issue than just inflated prices for drugs in short supply.
    May D
    Mod Healthc; 2011 Oct; 41(42):25. PubMed ID: 22049782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.